Stock Update: Merck & Co Inc (NYSE:MRK) – European Commission approves Merck’s $17 bln Sigma-Aldrich buy

[Reuters] – The European Commission said on Monday it had approved German drugmaker Merck’s $17 billion acquisition of Sigma-Aldrich Corp following the U.S. company’s pledges to sell assets in Germany. In May, Merck . . . → Read More: Stock Update: Merck & Co Inc (NYSE:MRK) – European Commission approves Merck’s $17 bln Sigma-Aldrich buy Similar Articles: Company Update: Merck & Co Inc (NYSE:MRK) – Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress Market Update (NYSE:MRK): Merck Announces Collaboration with the American Diabetes Association to Educate Adults with Diabetes About Increased Risk for Serious Diseases like Pneumococcal Pneumonia Stock Update (NYSE:MRK): Merck expects to be denied approval for sugammadex injection again